Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Phase I/II study of treatment of stage IV breast cancer with OKT3 x trastuzumab-armed activated T cells.

Lum LG, Rathore R, Cummings F, Colvin GA, Radie-Keane K, Maizel A, Quesenberry PJ, Elfenbein GJ.

Clin Breast Cancer. 2003 Aug;4(3):212-7. No abstract available.

PMID:
14499016
2.

Evaluation of HER2 status: for the treatment of metastatic breast cancers by humanized anti-HER2 Monoclonal antibody (trastuzumab) (Pathological committee for optimal use of trastuzumab).

Umemura S, Sakamoto G, Sasano H, Tsuda H, Akiyama F, Kurosumi M, Tokuda Y, Watanabe T, Toi M, Hasegawa T, Osamura RY.

Breast Cancer. 2001;8(4):316-20. Review.

PMID:
11791124
3.

Herceptin (trastuzumab): adjuvant and neoadjuvant trials.

Yaal-Hahoshen N, Safra T.

Isr Med Assoc J. 2006 Jun;8(6):416-21. Review. No abstract available.

4.

Trastuzumab (herceptin) for early-stage breast cancer.

Ismael G, Rosa DD, de Azambuja E, Braga S, Piccart-Gebhart M.

Hematol Oncol Clin North Am. 2007 Apr;21(2):239-56. Review.

PMID:
17512447
5.

Trastuzumab as the lead monoclonal antibody in advanced breast cancer: choosing which patient and when.

Olver IN.

Future Oncol. 2008 Feb;4(1):125-31. doi: 10.2217/14796694.4.1.125. Review.

PMID:
18241007
6.

Drug update: trastuzumab: anti-HER2 antibody for treatment of metastatic breast cancer.

Wong WM.

Cancer Pract. 1999 Jan-Feb;7(1):48-50. Review. No abstract available.

PMID:
9893005
7.

Gemcitabine and trastuzumab combinations for patients with metastatic breast cancer overexpressing HER2/neu.

Stein S, DeMichele A, Domchek S, Fox K.

Clin Breast Cancer. 2004 Jan;4 Suppl 3:S117-20. Review.

PMID:
14754469
8.

[HER2 testing in breast cancer].

Yoshimura K.

Nihon Rinsho. 2007 Jun 28;65 Suppl 6:275-80. Review. Japanese. No abstract available.

PMID:
17682167
10.

HER-2-positive metastatic breast cancer: trastuzumab and beyond.

Metro G, Mottolese M, Fabi A.

Expert Opin Pharmacother. 2008 Oct;9(15):2583-601. doi: 10.1517/14656566.9.15.2583 . Review.

PMID:
18803447
11.

The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.

Tokuda Y, Suzuki Y, Saito Y, Umemura S.

Breast Cancer. 2009;16(4):295-300. doi: 10.1007/s12282-009-0142-8. Epub 2009 Jul 17. Review.

PMID:
19609647
12.

Laboratory monitoring of therapy with OKT3 and other murine monoclonal antibodies.

Colvin RB, Preffer FI.

Clin Lab Med. 1991 Sep;11(3):693-714. Review.

PMID:
1934971
14.

Ongoing trials with trastuzumab in metastatic breast cancer.

Bell R.

Ann Oncol. 2001;12 Suppl 1:S69-73. Review.

PMID:
11521725
15.
16.

Trastuzumab-based combination therapy for breast cancer.

Montemurro F, Valabrega G, Aglietta M.

Expert Opin Pharmacother. 2004 Jan;5(1):81-96. Review.

PMID:
14680438
17.

Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.

Hortobagyi GN.

Semin Oncol. 2001 Dec;28(6 Suppl 18):43-7. Review.

PMID:
11774205
18.

Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research.

Goel S, Chirgwin J, Francis P, Stuart-Harris R, Dewar J, Mileshkin L, Snyder R, Michael M, Koczwara B.

Breast. 2011 Apr;20(2):101-10. doi: 10.1016/j.breast.2010.11.008. Epub 2010 Dec 22. Review.

PMID:
21183347
19.

Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.

Baselga J, Perez EA, Pienkowski T, Bell R.

Oncologist. 2006;11 Suppl 1:4-12. Review.

Supplemental Content

Support Center